Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19.

NCT04575597 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT04575597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04575597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19.
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2/3
Overall status
Completed
Start date
October 19, 2020
Completion date
May 5, 2022
Enrollment
1,735 (actual)
Sites
173

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease (covid-19)